Clinical Trial Update: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 vaccine with TLR agonist and/or Alum adjuvants in healthy adults. Results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Alum adjuvant (Aluminum-based adjuvant (alum))
• HIV-1 BG505 SOSIP.664 gp140 vaccine (BG505 SOSIP.664 gp140)
• TLR agonist adjuvant (TLR agonist)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2025-06-27